| Description |
1 online resource (279 pages). |
|
text file |
| Series |
Frontiers in Antimicrobial Agents ; v. 1
|
|
Frontiers in Antimicrobial Agents.
|
| Contents |
FOREWORD ; PREFACE ; List of Contributors ; Introduction ; INTRODUCTION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Bacteriophages as Antibacterial Agents: Why are We Facing an Antibiotic Crisis and How Could Bacteriophages be of Help? ; 1. INTRODUCTION; 2. WHY ARE WE FACING AN ANTIBIOTIC (AB) CRISIS? ; 3. HOW TO RESOLVE THIS ANTIBIOTIC CRISIS? ; 4. BACTERIOPHAGES OR IN SHORT 'PHAGES'; 5. BACTERIOPHAGE THERAPY OR PHAGE THERAPY; 6. EXPERIMENTAL PHAGE THERAPY; 7. SAFETY ISSUES; 8. IN FACT WE LIVE IN AN "OCEAN" OF BACTERIOPHAGES; 9. SAFETY REQUIREMENTS FOR PHAGE THERAPY. |
|
2.2. Applications of Immunotherapy2.3. Passive Immunotherapy; 2.4. Passive Immunotherapy: Antibodies ; 2.5. Passive Immunotherapy: Adoptive T-cell Transfer; 2.6. Passive Immunotherapy: Immunomodulators; 2.7. Growth Factors; 2.7.1. Filgastrim ; 2.7.2. Sargramostim ; 2.7.3. Erythropoietin (EPO) ; 2.7.4. Insulin-like Growth Factor-1 (IGF-1); 2.8. Interleukins; 2.8.1. Interleukin 2; 2.8.2. Interleukin-8; 2.9. Interferons; 2.9.1. Human Interferon Alpha (HuIFN- α); 2.9.2. Recombinant-Feline Interferon Omega (rFeIFN- ω) ; 2.10. Nonspecific Immunostimulants; 2.10.1. Staphylococcal Protein A (SPA). |
|
10. THE POTENTIAL ADVANTAGES OF PHAGE THERAPY VERSUS ANTIBIOTICS11. PHAGE THERAPY IN PUBLIC HEALTH; 12. WHY PHAGE THERAPY IS NOT YET IMPLEMENTED?; CONCLUSIONS AND PERSPECTIVES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Antimicrobial Peptides ; INTRODUCTION; 1. WHAT ARE ANTIMICROBIAL PEPTIDES (AMPS); 1.1. Mode of Action; 1.2. Immune System; 1.3. Resistance; 2. CHRONOLOGY OF AMPS DISCOVERY -- A BRIEF HISTORY; 2.1. Classification of AMPs; 2.1.1. Biological Source; 2.1.2. Biological Functions; 2.1.3. Biosynthesis; 2.1.4. Molecular Properties; 2.1.5. Molecular Targets. |
|
2.1.6. Three-Dimensional (3D) Structure2.2. Currently Active AMPs Databases; 3. THERAPEUTIC APPLICATIONS OF AMPS; 3.1. Anticancer AMPs; 3.2. Antiviral AMPs; 3.3. Anti-parasitic AMPs; 3.4. New Generation of AMPs; CONCLUDING REMARKS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Probiotics: Ways of Action and Beneficial Effects ; 1. INTRODUCTION; 2. SELECTION OF PROBIOTICS; 3. COMMERCIALLY IMPORTANT PROBIOTICS; 4. MECHANISMS OF ACTION OF PROBIOTICS; 4.1. Immunomodulation; 4.2. Direct Effects on Other Microorganisms; 5. BENEFICIAL HEALTH EFFECTS OF PROBIOTICS. |
|
5.1. Alleviation of Lactose Intolerance5.2. Effect on Helicobacter Pylori Eradication ; 5.3. Anti-carcinogenic Effect; 5.4. Cholesterol-lowering Effects; 5.5. Allergy and Atopic Dermatitis; 5.6. Inflammatory Diseases and Bowel Syndromes ; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Immunotherapy ; 1. BACTERIAL INFECTIVITY, IMMUNE RESPONSE AND MULTIRESISTANT INFECTIONS : NEW PERSPECTIVES; 1.1. Introduction; 1.2. Host Resistance; 1.3. Bacterial Strategies for Evading, Surviving Host Defense Systems and Create Infection; 2. IMMUNOTHERAPY; 2.1. Introduction. |
| Note |
2.10.2. Propionibacterium Acnes. |
| Bibliography |
Includes bibliographical references at the end of each chapters and index. |
| Local Note |
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - North America |
| Subject |
Drug resistance in microorganisms.
|
|
Drug resistance in microorganisms. |
| Added Author |
Serrano, Isa D.
|
| Other Form: |
Print version: Manuela, Oliveira. Challenges of antibiotic resistance in the development of new therapeutics. Sharjah : Bentham Science Publishers, ©2015 9781681081410 |
| ISBN |
1681081407 |
|
9781681081403 (electronic book) |
|
9781681081410 |
|
